GLEN ALLEN, Va., June 20, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the publication of previously disclosed results from its Phase 3 ONWARD study in a peer-reviewed article in the European Journal of Internal Medicine entitled, "Low-dose ondansetron: A candidate prospective precision medicine to treat al ...

Core Insights - Adial Pharmaceuticals published results from its Phase 3 ONWARD study in the European Journal of Internal Medicine, demonstrating the efficacy of AD04 (low-dose ondansetron) in reducing heavy drinking days among patients with Alcohol Use Disorder (AUD) and specific genetic profiles [1][2] Group 1: Study Findings - AD04 significantly decreased the monthly percentage of heavy drinking days after 6 months of treatment among heavy drinking individuals with AUD and a specific genetic profile [2] - The genetic profile involved variants in the serotonin transporter and serotonin-AB receptor complex [2] - Adverse events (AEs) associated with AD04 were comparable to those of the placebo, indicating a favorable safety profile [2][3] - The combination of AD04 with psychosocial interventions may enhance treatment perceptions and increase demand among individuals who might not have sought treatment otherwise [2] Group 2: Implications for Precision Medicine - The findings highlight the potential of AD04 as a precision medicine, emphasizing the importance of genetic and behavioral factors in treating AUD [2] - The study suggests that patients with specific genetic backgrounds who are heavy drinkers experienced a reduction in heavy drinking days after treatment with AD04 [2] - The research indicates that no existing studies in alcohol literature have shown a medication with a similar AE profile to a placebo, underscoring the uniqueness of AD04's safety profile [2] Group 3: Company Overview - Adial Pharmaceuticals is focused on developing treatments for addictions and related disorders, with AD04 being a genetically targeted therapeutic agent for AUD [3] - The ONWARD trial showed promising results in reducing alcohol consumption in heavy drinkers without significant safety concerns [3] - AD04 may also have potential applications in treating other addictive disorders such as Opioid Use Disorder, gambling, and obesity [3]

Making millions through the stock market is only possible in a few ways. Investors need one of these three things: Massive sums of capital to begin withDecades of time and more modest sums of capitalMore modest sums of capital and a combination of risk and luckWe will be talking about the latter today: seven stocks you can buy for $2 that can 10X by 2025. The standard caveat applies here, which says investors should only spend what they are willing to lose. Investing in sub-$2 stocks is very risky. Direct t ...

Study intended to optimize design elements needed for the upcoming US Pivotal Phase 3 studiesand support ongoing partnership discussions Topline results expected in early Q4 2024 GLEN ALLEN, Va., June 05, 2024 (GLOBE NEWSWIRE) --  Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced that the first patient has been dosed in a pharmacokineti ...

GLEN ALLEN, Va., May 29, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will be participating in the Spring MicroCap Rodeo Conference that will be held on Thursday, June 6, 2024 in New York City. Cary Claiborne, President and Chief Executive Officer of Adial, is scheduled to present at 2:00 p.m. ...

GLEN ALLEN, Va., May 29, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will be participating in the Spring MicroCap Rodeo Conference that will be held on Thursday, June 6, 2024 in New York City. Cary Claiborne, President and Chief Executive Officer of Adial, is scheduled to present at 2:00 p.m ...

GLEN ALLEN, Va., May 15, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the first quarter of 2024. Cary Claiborne, President and Chief Executive Officer of Adial, stated, "We are making steady progress as it relates to AD04. We have initiated new a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-38323 ADIAL PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 82-3074668 State ...

GLEN ALLEN, Va., April 22, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 11957664 was issued April 16, 2024 by the United States Patent and Trademark Office. This patent expands Adial's intellectual property protection and covers the combination of the Company's proprietary genetic diagno ...

Follow Invezz on Telegram , Twitter , and Google News for instant updates >Adial Pharmaceuticals Inc (NASDAQ: ADIL) is up 60% today following a promising update on its alcohol disorder drug.Are you looking for signals & alerts from pro-traders? Sign-up to Invezz Signals™ for FREE. Takes 2 mins.What it means for Adial Pharmaceuticals stock Copy link to section The $7.7 million company based out of Virginia, United States said its AD04 did well in a clinical trial of Alcohol Use Disorder (AUD) patients. Its l ...